Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera

Next Previous
X
Search
Trial Profile

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rusfertide (Primary)
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms VERIFY
  • Sponsors Protagonist Therapeutics

    • Most Recent Events

    • 17 Jul 2024 Status changed from recruiting to active, no longer recruiting.
    • 04 Jun 2024 Results comparing efficacy and safety of rusfertide (starting dose: 20 mg subcutaneously once weekly) vs. placebo when added to ongoing therapy for PV were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Mar 2024 According to a Protagonist Therapeutics media release, the REVIVE Phase 2 trial and other completed studies along with phase 3 pivotal trial will comprise the clinical data package planned for NDA filing in fourth quarter of 2025. Data from the 52-week endpoint for VERIFY including the durability of response expected in the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top